Enterprise Together with KSC
Deep Bio Inc.
Israel
Company Overview
Cancer diagnosis software based on AI-image analysis of pathology slides
Sectors
- Health IT
Project Summary
- AI Software for Cancer Diagnosis
Business Model
- Revenue model Software as a Service
- Key Customer Pathology labs or pathology departments in hospitals
Major Performance
-
Sales
- USD 42.1K (2019)
- USD 173.91K (2020)
-
Investment
- Cumulative funding of USD 16.76 M, (12 VCs including Neoplux)
-
Employees
- (2018) 22
- (2019) 20
- (2020) 27
-
Patent
- Applied: 21; Registered: 1
Overseas Expansion
Stage
Preparing to enter overseas markets
Status
Preparing for FDA approval; exhibitions at academic conferences in the US
Performance
- Provision of services to CLIA labs in the US
- Collaborative research and IRB underway with numerous renowned teaching hospitals in the US
- Currently ranked #1 in the Camelyon 17 Challenge (International AI competition for breast cancer lymph node metastasis detection)
Products / Services
1
2
- Target Country
- Israel
- Date of Establishment
- Oct. 8, 2015
-
- sales@deepbio.co.kr sales@deepbio.co.kr
-
- Website
- www.deepbio.co.kr www.deepbio.co.kr
-
- Location
- Guro-Gu, Seoul DeepDx
-
- CEO
- Sunwoo Kim
-
- Founder’s Background
-
- Deep Bio, Inc., CEO (2015~Current)
- Pinion Industries, CTO (2013~2014)
- KT, Deputy Director (2009~2013)
- NHN, Senior Manager (2008~2009)
- University of California, Irvine (UCI), Masters in Information and Computer Science (1999~2002)
- KAIST, B.S. in Computer Science (1991~1994)